Durham firm focusing on bioengineering of human tissue up to $150M in new capital

Humacyte has secured up to $150 million in new capital - including $40 million upfront - from Oberland Capital Management as the firm moves to commercialize bioengineered human tissue. Here are the details.

Related Keywords

Dale Sander , ,Oberland Capital Management ,Human Acellular Vessel ,Michael Bloom ,Oberland Capital ,Chief Financial Officer ,